Δ9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: Reduction in morphine withdrawal syndrome without change in rewarding effect

European Journal of Neuroscience

Volumn 13, Issue 9, 2001, Pages 1816-1824

  Valverde, Olga ^a,b   Noble, Florence ^a   Beslot, Françoise ^a   Daugé, Valérie ^a   Fournié Zaluski, Marie Claude ^a   Roques, Bernard P ^a  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Behaviour; Cannabinoids; Dependence; Met enkephalin; Mice; Microdialysis; Morphine

Indexed keywords

CANNABINOID; ENKEPHALIN; METENKEPHALIN; MORPHINE; N [3 [(2 AMINO 4 METHYLTHIO)BUTYLDITHIO] 2 BENZYLPROPIONYL]PHENYLALANINE BENZYL ESTER; NALOXONE; OPIATE; OPIATE RECEPTOR; TETRAHYDROCANNABINOL; TRITIUM; ANALGESIC AGENT; DIPRENORPHINE; DISULFIDE; DRUG DERIVATIVE; NARCOTIC AGENT; NARCOTIC ANTAGONIST; PHENYLALANINE; PSYCHOTROPIC AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; DRUG RESPONSE; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; REWARD; WITHDRAWAL SYNDROME; ANIMAL; BINDING COMPETITION; CONDITIONING; DRUG EFFECT; DRUG INTERACTION; EXTRACELLULAR SPACE; METABOLISM; MOTOR ACTIVITY; NERVE CELL; NOCICEPTIVE RECEPTOR; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANALGESICS; ANIMALS; BINDING, COMPETITIVE; CONDITIONING (PSYCHOLOGY); DIPRENORPHINE; DISULFIDES; DRUG INTERACTIONS; ENKEPHALIN, METHIONINE; EXTRACELLULAR SPACE; MALE; MICE; MORPHINE; MOTOR ACTIVITY; NARCOTIC ANTAGONISTS; NARCOTICS; NEURONS; NOCICEPTORS; NUCLEUS ACCUMBENS; PHENYLALANINE; PSYCHOTROPIC DRUGS; REWARD; SUBSTANCE WITHDRAWAL SYNDROME; TETRAHYDROCANNABINOL; TRITIUM;

EID: 0034744088     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0953-816X.2001.01558.x     Document Type: Article

References (47)

1. Abood, M.E. & Martin, B.R. (1996) Molecular neurobiology of the cannabinoid receptor. Int. Rev. Neurobiol., 39, 197-221.
2. Ameri, A. (1999) The effects of cannabinoids on the brain. Prog. Neurobiol., 58, 315-348.
3. 1 receptor stimulation. Eur. J. Pharmacol., 216, 157-166.
4. 9 -tetrahydrocannabinol in the mouse. Psychopharmacology, 57, 243-248.
5. Carney, J.M., Uwaydah, I.M. & Balster, R.L. (1977) Evaluation of a suspension system for intravenous self-administration studies of water-insoluble compounds in the rhesus monkey. Pharmacol. Biochem. Behav., 7, 357-364.
6. Cesselin. F., Oliveras, J.L., Bourgoin, S., Sierralta, F., Michelot, R., Besson, J.M. & Hamon, M. (1982) Increased levels of met-enkephalin-like material in the CSF of anaesthetized cats after tooth pulp stimulation. Brain Res., 237, 325-338.
7. 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther., 285, 1150-1156.
8. 9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. Life Sci., 61, 39-43.
9. 9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. Eur. J. Pharmacol., 323, 193-195.
10. Daugé, V., Mauborgne, A., Cesselin, F., Fournié-Zaluski, M.C. & Roques, B.P. (1996) The dual peptidase inhibitor RB101 induces a long-lasting increase in the extracellular level of met-enkephalin-like material in the nucleus accumbens of freely moving rats. J. Neurochem., 67, 1301-1308.
11. Felder, C.C. & Gloss, M. (1998) Cannabinoid receptors and their endogenous agonists. Annu. Rev. Pharmacol. Toxicol., 38, 179-200.
12. Fournié-Zaluski, M.C., Coric, P., Turcaud, S., Lucas, E., Noble, F., Maldonado, R. & Roques, B.P. (1992) Mixed-inhibitor-prodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes. J. Med. Chem., 35, 2473-2481.
13. Hine, B., Friedman, E., Torrelio, M. & Gershon, S. (1975) Morphine-dependent rats: Blockade of precipitated abstinence by tetrahydrocannabinol. Science, 187, 443-445.
14. Hollister, L.E. (1986) Health aspects of cannabis. Pharmacol. Rev., 38, 1-20.
15. 9-THC and anandamide. Brain Res., 857, 337-342.
16. 9-tetrahydrocannabinol. Br. J. Pharmacol., 125, 1567-1577.
17. Kameyama, T. & Nagasaka, M. (1982) Effects of apomorphine and diazepan in a quickly conditioned supression in rats. Pharmacol. Biochem. Behav., 17, 59-63.
18. Kónig, M., Zimmer, A.M., Steiner, H., Holmes, P.V., Crawley, J.N., Brownstein, M.J. & Zimmer, A. (1996) Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature, 383, 535-538.
19. Koob, G.F. & Le Moal, M. (1997) Drug abuse: Hedonic homeostatic dysregulation. Science, 278, 52-58.
20. Ledent, C., Valverde, O., Cossu, G., Petitet, F., Aubert, J.F., Beslot, F., Böhme, G.A., Imperato, A., Pedrazzini, T., Roques, B.P., Vassart, G., Fratta, W. & Parmentier, M. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1, receptor knockout mice. Science, 283, 401-404.
21. Leite, J.L. & Carlini, E.A. (1974) Failure to obtain 'cannabis directed behavior' and abstinence syndrome in rats chronically treated with cannabis saliva extracts. Psychopharmacologia, 36, 133-145.
22. 9-tetrahydrocannabinol comparison with cocaine, morphine, and food reward. Life Sci., 56, 2073-2080.
23. Maldonado, R., Negus, S. & Koob, G.F. (1992) Precipitation of morphine withdrawal syndrome in rats by administration of mu-delta-and kappa-selective opioid antagonists. Neuropharmacology, 31, 1231-1241.
24. 2 receptors. Nature, 388, 586-589.
25. 9-tetrahydrocannabinol and CP-55,940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys. Behav. Pharmacol., 5, 219-225.
26. Manzanares, J., Corchero, J., Romero, J., Fernandez-Ruiz, J.J., Ramos, J.A. & Fuentes, J.A. (1998) Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Brain Res. Mol. Brain Res., 55, 126-132.
27. Martellotta, M.C., Cossu, G., Fattore, L., Gessa, G.L. & Fratta, W. (1998) Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience, 85, 327-330.
28. Navarro, M., Chowen, J., Carrera, M.R.A., del Arco, I., Villanúa, M.A., Martín, Y., Roberts, A.J., Koob, G.B. & Rodríguez de Fonseca, F. (1998) CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport, 9, 3397-3402.
29. Noble, F., Soleilhac, J., Soroca-Lucas, E., Turcaud, S., Fournié-Zaluski, M.C. & Roques, B.P. (1992) Inhibition of enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB101 induces potent analgesic responses in mice and rats. J. Pharmacol. Exp. Ther., 261, 181-190.
30. Onaivi, E.S., Green, M.R. & Martin, B.R. (1990) Pharmacological characterization of cannabinoids in the elevated plus maze. J. Pharmacol. Exp. Ther., 253, 1002-1009.
31. Paxinos, G. & Watson, C. (1986) The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press, New York.
32. 9-tetrahydrocannabinol and morphine in the spinal cord. J. Pharmacol. Exp. Ther., 279, 608-616,
33. Rodríguez de Fonseca, F., Carreras, M.R.A., Navarro, M., Koob, G.F. & Weiss, F. (1997) Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science, 276, 2050-2054.
34. Roques, B.P., Noble, F., Daugé, V., Fournié-Zaluski, M.C. & Beaumont, A. (1993) Neutral endopeptidase 24.11: structure, inhibition and experimental and clinical pharmacology. Pharmacol. Rev., 45, 87-146.
35. 3H]diprenorphine binding. Brain Res., 571, 306-312.
36. Sanudo-Pena, M.C., Tsou, K., Delay, E.R., Hohman, A.G., Force, M. & Walker, J.M. (1997) Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci. Lett., 223, 125-128.
37. Simonin, F., Valverde, O., Smadja, C., Slowe, S., Kitchen, I., Dierich, A., Le Meur, M., Roques, B.P., Maldonado, R. & Kieffer, B.L. (1998) Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J., 17, 886-897.
38. 9-tetrahydrocannabinol and kappa opioids in mice. J. Pharmacol. Exp. Ther., 268, 1381-1387.
39. 9-tetrahydrocannabinol by rats. Pharmacol. Biochem. Behav., 11, 737-740.
40. 1 opioid receptor mechanism. Science, 276, 2048-2050.
41. 9-tetrahydrocannabinol in mice. Psychopharmacology, 147, 436-438.
42. Valverde, O., Ledent, C., Beslot, F., Parmentier, M. & Roques, B.P. (2000) Reduction of stress-induced analgesia but not exogenous opioid effects in mice lacking CB1 receptors. Eur. J. Neurosci., 12, 533-539.
43. Valverde, O., Maldonado, R., Fournié-Zaluski, M.C. & Roques, B.P. (1994) CCK-B receptor antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J. Pharmacol. Exp. Ther., 270, 77-88.
44. Van Ree, J.M., Slangen, J. & de Wied, D. (1978) Intravenous self-administration of drugs in rats. J. Pharmacol. Exp. Ther., 20, 547-557.
45. Vela, G., Ruiz-Gayo, M. & Fuentes, J.A. (1995) Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology, 34, 665-668.
46. Welch, S.P. & Stevens, D.L. (1992) Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J. Pharmacol. Exp. Ther., 262, 10-18.
47. Zimmer, A., Zimmer, A.M., Hodmann, A.G., Herkenham, M. & Bonner, T.I. (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA, 96, 5780-5785.